BTIG lowered the firm’s price target on MDxHealth (MDXH) to $4 from $7 and keeps a Buy rating on the shares after its Q1 miss and “material guidedown for 2026”. The company disclosed it obtained a notice from Medicare contractor Novitas for a recoupment payment of about $10M related to prior payments received for its Resolve UTI test, and while MDxHealth views this action as without merit and is vigorously defending its position, the management proactively decided to discontinue the test and is shutting down the TX lab that was running the test, the analyst tells investors in a research note.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MDXH:
- Mdxhealth Exits Resolve Business, Refocuses on Prostate Cancer as Q1 2026 Revenue Rises 13%
- MDxHealth reports Q1 EPS (17c) vs. (19c) last year
- Mdxhealth S.A. (MDXH) Q1 Earnings Cheat Sheet
- MDxHealth Sets May 28, 2026 Shareholders’ Meetings to Approve 2025 Accounts and Governance Moves
- MDxHealth management to meet virtually with Willlam Blair